Project Grant R25TR005269

Award Date 5/1/24
Completion Date 4/30/27
Dollars Obligated $199K
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) provides $1,049,035.00 to The Children's Hospital of Philadelphia to harmonize and curate a natural history database for Metachromatic Leukodystrophy (MLD), a rare and fatal neurological disease. The project aims to create a rigorous, regulatory-ready database (MLD-CORE) and a public web platform (MLD-LINK) to...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $178,000.00 to The Children's Hospital of Philadelphia (CHOP) to design and validate a Pelizaeus Merzbacher Disease (PMD) severity scale. The goal is to develop a clinician-reported outcome measure that can be used to stratify PMD patients by disease severity, particularly early in the disease...
This Project Grant award of $401,566.00 from the National Center for Advancing Translational Sciences (CFDA 93.350) to The Trustees of the University of Pennsylvania aims to advance research on LCAT deficiency, an ultra-rare genetic disorder. The key objectives are to: 1) Identify biomarkers to guide patient enrollment and monitor efficacy for potential treatments, including distinguishing between the two LCAT deficiency syndromes (Familial LCAT Deficiency and Fish-Eye Disease); 2) Determine...
This Project Grant award of $1,313,434 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to unravel the genomic causes of unsolved leukodystrophy patients. The primary awardee, Children's Mercy Hospital, will utilize advanced long-read genome sequencing (HiFi-GS) to identify complex genetic variants, such as repeat expansions and structural variants, that may account for missed...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a new therapy for neurodevelopmental mitochondrial disorders. The $105,625 award to the Icahn School of Medicine at Mount Sinai, from August 1, 2024 to July 31, 2026, will support two main objectives: 1) analyzing how a specific succinyl-CoA precursor is...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,507,286.11 over 3 years starting September 1, 2024 to conduct a comparative mechanistic investigation of three potential therapies for Down Syndrome Regression Disorder (DSRD). The research aims to 1) define the relative safety profile of the benzodiazepine lorazepam, intravenous immunoglobulin (IVIG), and the JAK inhibitor...
This federal Project Grant award, provided by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, supports the development of a novel murine model of combined D/L-2-hydroxyglutaric aciduria (D/L-2HGA), a rare genetic disorder. The $156,000 award to Georgetown University will enable researchers to identify the pathways by which the D- and L-2HG enantiomers are produced in the context of SLC25A1 gene mutations, and assess how these enantiomers affect...
This federal Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) totaling $1,276,313 aims to explore ethical challenges and develop management strategies for patient-focused drug development (PFDD) in rare disease research. The primary objectives are to: 1) conduct stakeholder interviews to identify ethical challenges in PFDD, 2) characterize stakeholder values, interests, and relationships to pinpoint areas of conflict and alignment, and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $2,013,258 to the University of Massachusetts Medical School (UMass Medical) to develop an AAV gene therapy for the rare lysosomal storage disorder sialidosis. The project aims to: 1) determine the minimum effective dose and maximum tolerated dose of the AAV9-NEU1-BICI-CTSA construct...

PREDOCTORAL PREPARATORY PROGRAM (P3) IN TRANSLATIONAL RESEARCH - PROJECT SUMMARY/ABSTRACT LEUKODYSTROPHIES ARE A COLLECTION OF RARE GENETIC DISORDERS THAT AFFECT CEREBRAL MYELIN DEVELOPMENT. EXCITING RECENT THERAPEUTIC ADVANCES, INCLUDING GENE THERAPY DEVELOPMENT FOR ADRENOLEUKODYSTROPHY AND METACHROMATIC LEUKODYSTROPHY, UNDERSCORE THE CRITICAL UNMET NEED FOR THERAPEUTIC DEVELOPMENT MORE BROADLY ACROSS THE LEUKODYSTROPHIES. THE FUTURE OF INNOVATION, HOWEVER, IS LIMITED BY THE PIPELINE OF FUTURE TRANSLATIONAL RESEARCHERS INTERESTED IN RARE DISEASES. THE RARE DISEASES CLINICAL RESEARCH NETWORK (RDCRN) GLOBAL LEUKODYSTROPHY INITIATIVE CLINICAL TRIALS NETWORK (GLIA-CTN; U54TR002823) IS AN NIH-FUNDED RESEARCH CONSORTIUM FOR LEUKODYSTROPHY COLLABORATION AND INNOVATION ACROSS A NETWORK OF 8 LARGE US-BASED ACADEMIC INSTITUTIONS. THIS INFRASTRUCTURE PROVIDES A UNIQUE OPPORTUNITY TO RECRUIT AND SUPPORT THE NEXT GENERATION OF RARE DISEASE RESEARCH LEADERS. WE HYPOTHESIZE THAT A FORMAL EDUCATION PROGRAM IN RARE DISEASE RESEARCH TARGETING JUNIOR RESEARCH COORDINATORS WHO ARE EARLY IN THEIR CAREER WILL FACILITATE LONG-TERM COMMITMENT AND PASSION FOR RARE DISEASE RESEARCH. THIS IS A POPULATION THAT IS ENRICHED WITH YOUNG SCHOLARS INTERESTED IN SCIENCE WHO ARE OFTEN UNDECIDED ABOUT CAREER PATHS OR HAVE HAD INSUFFICIENT EXPOSURE TO TRANSLATIONAL RESEARCH. THE PROPOSED PROGRAM REPRESENTS A NOVEL COLLABORATION BETWEEN THE LEUKODYSTROPHY CENTER OF EXCELLENCE (LCE) AT THE CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP), A GLIA-CTN SITE, AND THE INSTITUTE FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS EDUCATION (ITMAT ED) PROGRAMS AT THE PERELMAN SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA. IN 2021-2022, THE LCE AND ITMAT ED PILOTED THE PREDOCTORAL PREPARATORY PROGRAM (P3) WITH 8 JUNIOR RESEARCH COORDINATORS, KNOWN AS P3 SCHOLARS, BASED EXCLUSIVELY WITHIN THE CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP). IN 2022-2023, THE PROGRAM EXPANDED TO INCLUDE 14 COORDINATORS WORKING AT SITES ACROSS THE GLIA-CTN. EACH YEAR WE AIM TO ENROLL 12-15 SCHOLARS WHO ARE JUNIOR RESEARCH COORDINATORS WORKING WITHIN THE GLIA-CTN. WE RECOGNIZE THE IMPORTANCE OF DIVERSITY AMONG FUTURE TRANSLATIONAL RESEARCH LEADERS AND WILL CONTINUE TO RECRUIT FROM POPULATIONS UNDERREPRESENTED IN MEDICINE (UIM). IN THIS APPLICATION, WE PROPOSE AN EDUCATION PROGRAM, THE PREDOCTORAL PREPARATORY PROGRAM (P3), WHICH WILL (1) PROVIDE A CURRICULUM RELATED TO RESPONSIBLE CONDUCT OF RESEARCH AND (2) PREPARE THE NEXT GENERATION OF PHYSICIAN SCIENTISTS IN TRANSLATIONAL RESEARCH THROUGH PROFESSIONAL DEVELOPMENT WORKSHOPS AND MENTORSHIP. THIS PROPOSAL IS TO FURTHER THE DEVELOPMENT AND IMPLEMENTATION OF A ONE-YEAR PROGRAM FOCUSED ON RESEARCH AND PROFESSIONAL SKILLS DEVELOPMENT, COMMUNITY BUILDING, AND MENTORSHIP WHICH IS FULLY INTEGRATED INTO A HANDS-ON RESEARCH EXPERIENCE THROUGH THE GLIA-CTN RESEARCH NETWORK.

Posted 4/22/24, 12:00 AM